Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01967628 · ClinicalTrials.gov registry record · Phase 1
Human Lung Responses to Respiratory Pathogens
A Phase 1 study, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT01967628 is a Phase 1 study that has completed, run by University of Iowa. The registered enrollment target is 98 participants.
The verdict
NCT01967628, a Phase 1 study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
For most individuals, the lung has a remarkable ability to deal with exposure to a variety of inhaled bacteria. Some individuals, however, do have recurrent bacterial infections, usually in the form of acute or chronic bronchitis and, in some instances, pneumonia. The reasons for this variability in bacterial infections between otherwise healthy subjects, between types of lung disease, and within the same type of lung disease are poorly understood. Variability in susceptibility to bacterial infections is partially explained by differences in exposure to infectious agents, genetic susceptibility and innate (or early) immune responses. It is of interest that the incidence and severity of bacterial infections is greatest during the winter months. Other than viral infections, there are few variables that change with season. Vitamin D is one known immune modulator with a seasonal periodicity. The hypothesis of this study is that levels of vitamin D are an important determinant of the innate defense of the lung against inhaled bacteria. The investigators further postulate that vitamin D has effects on the innate immune function of both alveolar macrophages and lung epithelial cells.
Interventions
- DIETARY_SUPPLEMENT Vitamin D3 (cholecalciferol)
- DIETARY_SUPPLEMENT Placebo Sugar Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01967628
The ClinicalTrials.gov registry entry for NCT01967628 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vitamin D3 (cholecalciferol) is the first listed.
NCT01967628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01967628 about?
NCT01967628 is a clinical study titled "Human Lung Responses to Respiratory Pathogens". For most individuals, the lung has a remarkable ability to deal with exposure to a variety of inhaled bacteria. Some individuals, however, do have recurrent bacterial infections, usually in the form of acute or chronic bronchitis and, in some instances, pneumonia. The reasons for this variability in...
What is the current status of trial NCT01967628?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2007-06. Estimated completion is 2010-10.
What interventions are being tested in trial NCT01967628?
The interventions under investigation include: Vitamin D3 (cholecalciferol) (DIETARY_SUPPLEMENT), Placebo Sugar Pill (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01967628?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.